Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities

• Published in: Scientific reports Vol. 8; no. 1; pp. 7781 - 7
• Main Authors: Farrokhi, Vahid, Chabot, Jeffrey R., Neubert, Hendrik, Yang, Zhiyong
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 17.05.2018; Nature Publishing Group
• Subjects: 631/154/51/1568; 631/1647/296; 631/250/249; 82/1; 82/58; 96/21; Amino acids; Animals; Antibodies; Antibodies, Monoclonal - pharmacology; Antibodies, Neutralizing - pharmacology; Cancer; Cell survival; Cell-mediated immunity; Feasibility Studies; Fibrosis; Humanities and Social Sciences; Humans; Immunoglobulins; Mass spectrometry; Mass spectroscopy; Metastases; Mineralization; Models, Biological; multidisciplinary; Neutralization; Osteopontin; Osteopontin - antagonists & inhibitors; Osteopontin - immunology; Osteopontin - pharmacokinetics; Pharmaceutical industry; Pharmacodynamics; Pharmacokinetics; Physiology; Rheumatoid arthritis; Science; Science (multidisciplinary); Stable isotopes; Tumorigenesis
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-26187-w

Osteopontin is a secreted glycophosphoprotein that is highly implicated in many physiological and pathological processes such as biomineralization, cell-mediated immunity, inflammation, fibrosis, cell survival, tumorigenesis and metastasis. Antibodies against osteopontin have been actively pursued as potential therapeutics for various diseases by pharmaceutical companies and academic laboratories. Many studies have demonstrated the efficacy of osteopontin inhibition in a variety of preclinical models of diseases such as rheumatoid arthritis, cancer, nonalcoholic steatohepatitis, but clinical utility has not yet been demonstrated. To evaluate the feasibility of osteopontin neutralization with antibodies in a clinical setting, we measured its physiological turnover rate in humans, a sensitive parameter required for mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of biotherapeutics. Results from a stable isotope-labelled amino acid pulse-chase study in healthy human subjects followed by mass spectrometry showed that osteopontin undergoes very rapid turnover. PK/PD modeling and simulation of different theoretical scenarios reveal that achieving sufficient target coverage using antibodies can be very challenging mostly due to osteopontin’s fast turnover, as well as its relatively high plasma concentrations in human. Therapeutic antibodies against osteopontin would need to be engineered to have much extended PK than conventional antibodies, and be administered at high doses and with short dosing intervals.